Showing results (171-180 of 213) with videos related to
Sort By:
Pageof 22
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.Journal for Immunotherapy of Cancer|June 5, 2021
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine releaseKevin Dang, Giulia Castello, Starlynn C Clarke, et al.Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.Journal for Immunotherapy of Cancer|April 20, 2024
Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitisJun Yan He, Yang-Joon Kim, Elvira Mennillo, et al.Journal for Immunotherapy of Cancer|August 28, 2021
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, et al.The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.Journal for Immunotherapy of Cancer|May 13, 2021
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.Pageof 22